Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Combined With IT Regimen for Recurrent or Refractory Neuroblastoma
NCT05027386Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2021
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Rivoceranib in neuroblastoma (4 arms), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 6 months. Started Aug 2021; status: completed.
02
Drugs
Rivoceranib
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT05027386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05027386.